Progenics Pharmaceuticals Announces the Completion of Enrollment of Chemotherapy Naive Cohort in Phase II Trial of PSMA ADC

“Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, announced today the completion of enrollment in the chemotherapy naïve cohort in its Phase II trial of PSMA ADC.   This cohort of 36 chemotherapy naïve prostate cancer patients, all of whom progressed on hormonal therapies, was added to the Phase II trial following positive response to PSMA ADC in patients in the chemotherapy experienced setting.”

Editor’s note: This story is about clinical trial NCT01695044. The trial is testing a treatment called PSMA ADC for patients with metastatic, castration-resistant prostate cancer. Clinical trials can be good treatment options for some patients. Learn more about them here.


New Target for Prostate Cancer Resistant to Anti-Hormone Therapies

“Prostate cancer becomes deadly when anti-hormone treatments stop working. Now a new study suggests a way to block the hormones at their entrance.

“Researchers from the University of Michigan Comprehensive Cancer Center have found that a protein called BET bromodomain protein 4 binds to the hormone androgen receptor downstream of where current therapies work – targeting androgen receptor signaling.

“This could mean that when prostate cancer becomes resistant to current treatments, it might remain sensitive to a drug that targets BET bromodomain proteins. Results appear inNature.”

Editor’s note: The drug described in this story, JQ1, will likely soon be offered to prostate cancer patients through clinical trials.


Radical Treatment for Advanced Prostate Cancer May Herald Major Survival Advantage Over Conventional Treatment

“Controversial new research may overturn the standard treatment of men with advanced prostate cancer. Work indicates that men with advanced prostate cancer could have a better chance of surviving if they undergo treatment directed specifically at the prostate (so-called ‘radical’ therapy) as well as hormonal treatment.”


Thematic Session 10: Update on treatment options for patients with CRPC

“There are new treatment options for castration resistant prostate cancer (CRPC) but finding the optimal strategy and selecting the right patient is still fraught with challenges and difficulties, according to uro-oncology experts during a thematic session at the 29th Annual EAU Congress in Stockholm, Sweden.

“ ‘With many prostate cancer patients hoping for a better life without symptoms of the disease, the aim is to identify which new drugs, or a combination of these drugs, can offer prolong survival or effectively palliate bone disease,’ said Prof. Maria De Santis who chaired Thematic Session 10.

“The session focussed on castration-resistant prostate cancer (CRPC) which is often considered one of the toughest challenges in uro-oncology since despite repeated treatments the disease accelerates or progresses with severe impact on quality of life (QoL).”

Editor’s note: This article is about an event at a urology conference in Sweden. During the event, participants discussed the latest in prostate cancer treatment, with a focus on castration-resistant prostate cancer (CRPC).


Six Months Hormone Therapy in Addition to Radiotherapy Improves Prostate Cancer Survival

“Vienna, Austria: Men with prostate cancer that is small and confined to the prostate gland but that is at risk of growing and spreading, do better if they are treated with radiotherapy combined with androgen deprivation therapy, which lowers their levels of the male hormone, testosterone, according to new research.”


Should the Primary Tumor Be Treated in Patients With Metastatic Prostate Cancer?

“Researchers at The University of Texas MD Anderson Cancer Center hope to determine whether treating the primary tumor has any oncologic benefit in patients with metastatic prostate cancer.

“A new clinical trial aims to find which patients, if any, are most likely to benefit from such treatment.

“The prostate tumor usually is not treated in patients with metastatic disease unless the tumor progresses and causes local symptoms. Instead, patients typically undergo a sequence of systemic therapies, starting with hormone therapy (also called androgen deprivation), which can be done by orchiectomy but is most often done with injections of luteinizing hormone–releasing hormone agonists or antagonists. Unfortunately, complications from local progression occur in 30%–45% of patients whose primary prostate tumors have not been previously treated with radiation or surgery.”

Editor’s note: We previously posted a story that showed that treating the primary tumor may prolong survival times for some with metastatic prostate cancer.


Enzalutamide Improved Outcomes in Prostate Cancer Regardless of Age

“Enzalutamide significantly prolonged OS, radiographic PFS and time to PSA progression in both younger and older patients with metastatic castration-resistant prostate cancer, according to a post-hoc analysis of the phase 3 AFFIRM trial.

“The original analysis of the randomized, double blind trial indicated that patients with prostate cancer who previously received docetaxel chemotherapy demonstrated improved median OS when treated with enzalutamide (Xtandi, Astellas Pharma) — an oral androgen receptor inhibitor — compared with patients assigned placebo (18.4 months vs. 13.6 months; HR=0.63; 95% CI, 0.53-0.75).”


Hormone Therapy Linked to Better Survival after Lung Cancer Diagnosis in Women

“Survival among people with lung cancer has been better for women than men, and the findings of a recent study indicate that female hormones may be a factor in this difference. The combination of estrogen plus progesterone and the use of long-term hormone therapy were associated with the most significant improvements in survival.

“The study was designed to explore the influence of several reproductive and hormonal factors on overall survival of women with non-small cell lung cancer (NSCLC). After adjusting for stage of disease at diagnosis, treatment type (surgery or radiation), smoking status, age, race, and education level, the only factor studied that predicted survival after a diagnosis of NSCLC was use of hormone therapy.”


Prostate Cancer Advance Could Improve Treatment Options

“Researchers have made an important advance in understanding genetic changes associated with terminal prostate cancer. The research highlights why relapses could happen in some men following hormone therapy. And it could help identify those patients that will develop fatal prostate cancer much earlier for life-extending therapy.”